VYNE Therapeutics Inc. (NASDAQ:VYNE – Get Free Report) saw a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 88,000 shares, a growth of 1,157.1% from the December 15th total of 7,000 shares. Based on an average trading volume of 401,800 shares, the short-interest ratio […]
Clinical-stage biopharma company VYNE Therapeutics Inc. (VYNE) Wednesday announced that its BET inhibitor had a positive effect on multiple disease-associated biomarkers in patients with non-segmental vitiligo.
VYNE Therapeutics Inc. (NASDAQ:VYNE – Get Free Report) saw a significant drop in short interest in the month of December. As of December 15th, there was short interest totalling 7,000 shares, a drop of 94.4% from the November 30th total of 124,800 shares. Based on an average daily volume of 366,400 shares, the days-to-cover ratio […]
VYNE Therapeutics (NASDAQ:VYNE – Get Free Report) and Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership. Valuation and Earnings This table compares VYNE Therapeutics […]
VYNE Therapeutics (NASDAQ:VYNE – Free Report) had its target price cut by HC Wainwright from $28.00 to $5.75 in a research note issued to investors on Monday morning, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for VYNE Therapeutics’ Q3 2023 earnings at ($0.76) EPS, Q4 2023 […]